US 12,496,282 B2 · Hepatitis B antiviral agents

Abstract

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Claims11

Dependent claims

A method of treating a hepatitis B virus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of

(i) a compound represented by the formula
wherein R is hydrogen or fluorine;
and
(ii) a therapeutic agent selected from the group consisting of viral entry inhibitors, capsid assembly modulators, reverse transcriptase inhibitors, and TLR-agonists.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

18/660,695Filed 10 May 2024 · continuation

Priority

28 Aug 2017

Published

US 2024/0366538 A17 Nov 2024

Granted

16 Dec 2025

Term ends

Not estimatedThe source records don’t support an estimate.

Classification79 codes

A61K 31/167
Having aromatic rings, e.g. colchicine, atenolol, progabide: having the nitrogen of a carboxamide group directly attached to the aromatic ring,…
A61K 31/337
Having oxygen as the only ring hetero atom, e.g. fungichromin: having four-membered rings, e.g. taxol
A61K 31/34
Having oxygen as the only ring hetero atom, e.g. fungichromin: having five-membered rings with one oxygen as the only ring hetero atom, e.g.…
A61K 31/351
Having six-membered rings with one oxygen as the only ring hetero atom: not condensed with another ring

Family

Application62/550,992Us provisional application · filed 28 Aug 2017

Application16/114,842Parent of this division · filed 28 Aug 2018

Application17/166,046Parent of this continuation · filed 3 Feb 2021

US 10,952,978 B2Parent of this division · filed 23 Mar 2021

Application18/101,258Parent of this continuation · filed 25 Jan 2023

US 11,596,611 B2Parent of this continuation · filed 7 Mar 2023

US 2024/0366538 A1Pre-grant publication · published 7 Nov 2024

US 12,011,425 B2Parent of this continuation

Application17/166,046Parent of this division

US 2019/0060258 A1Published application

US 2021/0283077 A1Published application

US 2023/0241012 A1Published application

US 12,496,282 B2This patent

From the US filing history. Foreign family members aren’t listed.

Hepatitis B antiviral agents

Life of this patent

Hepatitis B antiviral agents

Life of this patent

Abstract

Claims11